Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Non-Current Debt (2017 - 2025)

Dr Reddys Laboratories (RDY) has 8 years of Non-Current Debt data on record, last reported at $72.1 million in Q1 2024.

  • For Q1 2024, Non-Current Debt rose 363.95% year-over-year to $72.1 million; the TTM value through Mar 2024 reached $72.1 million, up 363.95%, while the annual FY2025 figure was $92.0 million, 27.14% up from the prior year.
  • Non-Current Debt reached $72.1 million in Q1 2024 per RDY's latest filing, up from $15.5 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $86.4 million in Q1 2021 and bottomed at $15.5 million in Q1 2023.
  • Average Non-Current Debt over 5 years is $53.7 million, with a median of $72.1 million recorded in 2024.
  • Peak YoY movement for Non-Current Debt: plummeted 94.23% in 2020, then surged 379.95% in 2021.
  • A 5-year view of Non-Current Debt shows it stood at $18.0 million in 2020, then soared by 379.95% to $86.4 million in 2021, then decreased by 11.54% to $76.4 million in 2022, then plummeted by 79.66% to $15.5 million in 2023, then soared by 363.95% to $72.1 million in 2024.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $72.1 million in Q1 2024, $15.5 million in Q1 2023, and $76.4 million in Q1 2022.